The semaglutide peptide is a 31-amino-acid synthetic GLP-1 receptor agonist modified with an alpha-aminoisobutyric acid substitution at position 8 and a C18 fatty diacid side chain at lysine-26. Supplied exclusively as a research-grade compound for in vitro and laboratory investigation, its engineered sequence exhibits extended albumin binding and enzymatic resistance compared to endogenous GLP-1(7-37).
The semaglutide peptide is a 31-amino-acid synthetic GLP-1 receptor agonist modified with an alpha-aminoisobutyric acid substitution at position 8 and a C18 fatty diacid side chain at lysine-26. Supplied exclusively as a research-grade compound for in vitro and laboratory investigation, its engineered sequence exhibits extended albumin binding and enzymatic resistance compared to endogenous GLP-1(7-37).
The semaglutide peptide sequence is derived from native human glucagon-like peptide-1 (GLP-1), specifically the truncated bioactive form GLP-1(7-37). To overcome the rapid enzymatic degradation characteristic of endogenous incretins, the sequence incorporates specific chemical modifications designed to extend plasma half-life while preserving binding affinity for the GLP-1 receptor (GLP-1R). Researchers examining semaglutide synthetic peptide samples utilize detailed primary sequence data to confirm structural identity via mass spectrometry.
The primary semaglutide amino acid sequence consists of 31 amino acid residues. In standard single letter notation, the backbone sequence is represented as H-H-[Aib]-E-G-T-F-T-S-D-V-S-S-Y-L-E-G-Q-A-A-K(Linker-Diacid)-E-F-I-A-W-L-V-R-G-R-G-OH. The critical modifications include the substitution of L-alanine at position 8 with alpha-aminoisobutyric acid (Aib), and the attachment of a C-18 fatty diacid (17-carboxyheptadecanoyl) linked via a gamma-glutamic acid (γ-Glu) and two 2-(2-(2-aminoethoxy)ethoxy)acetic acid (OEG/AEEA) spacer units to the epsilon-amino group of Lysine at position 26.
When analyzing the ozempic amino acid sequence alongside human native GLP-1(7-37), key structural variations account for the marked difference in biological degradation rates observed in preclinical assays. Native GLP-1 possesses an L-alanine at position 8, making it an immediate substrate for dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal H2N-His7-Ala8 dipeptide within minutes in cellular media.
By substituting L-alanine with the non-proteinogenic amino acid alpha-aminoisobutyric acid (Aib8), the semaglutide sequence introduces steric hindrance around the N-terminus. This structural alteration renders the semaglutide research peptide resistant to DPP-4 cleavage without impairing its interaction with the GLP-1 receptor orthosteric binding site. Furthermore, the hydrophilic OEG spacer and C18 fatty diacid side chain attached to Lys26 promote reversible non-covalent binding to serum albumin, protecting the peptide backbone from renal clearance in animal models.
In cell-free and cell-based assay systems, the semaglutide synthetic peptide functions as a potent, full agonist at the human GLP-1 receptor. Receptor binding assays demonstrate that semaglutide retains high nanomolar binding affinity for GLP-1R despite the bulky hydrophobic fatty acid modification at Lys26. The bifunctional OEG linker places the fatty acid group at an optimal orientation, minimizing steric clash with the receptor's extracellular domain while maintaining high affinity for the hydrophobic binding pockets of albumin.
Preclinical studies suggest that upon binding to GLP-1R, semaglutide stimulates adenylate cyclase activity, triggering cyclic adenosine monophosphate (cAMP) accumulation and downstream activation of protein kinase A (PKA) and Epac2 pathways. Researchers investigating incretin mimetics measure these intracellular signaling cascades to quantify receptor activation kinetics across different target tissue preparations.
In vitro data indicate that semaglutide research peptides display distinct physical-chemical stability profiles compared to native peptide hormones. In primary islet cell cultures and immortalized pancreatic beta-cell lines (such as INS-1E or MIN6 cells), exposure to semaglutide induces glucose-dependent insulin release profiles while suppressing glucagon gene expression.
Rodent metabolic models—including ob/ob mice, db/db mice, and diet-induced obesity (DIO) rat strains—are routinely used to measure the pharmacodynamic effects of semaglutide sequence variations. In these animal research models, administration of purified semaglutide leads to reduced food intake, delayed gastric emptying rates, and improved glycemic control. These preclinical outcomes provide valuable comparative benchmarks when evaluating novel peptides semaglutide analogs or co-agonist formulations in experimental workflows.
To contextualize the signaling potency and structural efficacy of the semaglutide sequence, researchers frequently compare it against older monogenic incretins and multi-target receptor agonists within the same functional family. Evaluating these structural differences helps illuminate how specific sequence edits modulate receptor selectivity.
For example, liraglutide utilizes a single C16 palmitoyl chain at Lys26 without the Aib8 substitution, resulting in a shorter circulatory half-life in rodent models than semaglutide. Conversely, multi-receptor agonists like tirzepatide incorporate a 39-amino-acid GIP-derived sequence modified with a C20 fatty acid side chain, providing dual GLP-1 and GIP receptor activation. Emerging triple-agonist research standards like retatrutide further expand this paradigm by co-activating GLP-1, GIP, and glucagon receptors. Investigating combinations such as semaglutide alongside amylin analogs like cagrilintide allows laboratory teams to assess additive pathways in body weight and metabolic regulation assays.
Because small impurities, sequence truncation, or uncoupled side chains can compromise experimental reproducibility, acquiring verified semaglutide research peptides requires rigorous analytical testing. Academic and commercial laboratories rely on validated chemical testing frameworks to ensure batch uniformity.
PX1 Research enforces strict quality assurance protocols for all analytical reference compounds. Every lot of semaglutide synthetic peptide undergoes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm high purity (typically ≥99.0%) and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify the target molecular weight of 4113.58 Da. In addition, endotoxin testing using chromogenic LAL assays confirms levels remain below strict laboratory limits (<0.01 EU/mg), ensuring compatibility with sensitive cell cultures. Detailed documentation is accessible directly through our peptides research catalog.
Proper reconstitution and handling of the semaglutide research peptide are critical to prevent peptide aggregation or hydrolytic cleavage during in vitro experimentation. Due to the hydrophobic nature of the C18 fatty diacid side chain, dissolution parameters must be carefully managed according to analytical protocol standards.
Lyophilized semaglutide powder should be reconstituted using sterile bacteriostatic water or buffered aqueous solutions (such as phosphate-buffered saline, pH 7.4). Gentle agitation should be applied without vortexing, as high-shear mechanical agitation can induce fibril formation or protein denaturation. Reconstituted aliquots should be stored at -20°C to -80°C to prevent degradation, avoiding repeated freeze-thaw cycles. Detailed protocols for handling research peptides are outlined in the PX1 laboratory research hub.
When purchasing semaglutide sequence standards for analytical testing or cellular assays, laboratory managers must prioritize vendor transparency, batch traceability, and facility compliance. Substandard synthetic peptides containing residual trifluoroacetic acid (TFA) salts or unreacted lipid linkers can confound binding assays and toxicity assays.
PX1 Research manufactures all research compounds in USA-based GMP-compliant facilities and verifies purity through independent ISO 17025 accredited testing laboratories. Every order includes a lot-specific Certificate of Analysis (COA) detailing HPLC chromatograms and mass spectra. To support uninterrupted laboratory schedules, orders placed Monday through Friday ship same-day from our fulfillment centers in California and Arizona. For high-volume screening or institutional procurement, explore our bulk laboratory supply options.
What is the semaglutide peptide sequence in single letter code?
The semaglutide sequence in single letter amino acid code is H-H-[Aib]-E-G-T-F-T-S-D-V-S-S-Y-L-E-G-Q-A-A-K(Spacer-C18Diacid)-E-F-I-A-W-L-V-R-G-R-G-OH. Position 8 contains alpha-aminoisobutyric acid (Aib), and position 26 contains a modified Lysine residue bound to a hydrophilic OEG linker and a C18 fatty diacid side chain.
How does the semaglutide amino acid sequence differ from native human GLP-1?
The semaglutide amino acid sequence differs from native GLP-1(7-37) in two key areas: L-alanine at position 8 is replaced by alpha-aminoisobutyric acid (Aib) to prevent DPP-4 degradation, and Lysine at position 26 is conjugated with a C18 fatty acid chain via an OEG spacer to enable reversible albumin binding.
What is the molecular weight of the semaglutide research peptide?
The theoretical molecular weight of the semaglutide synthetic peptide is 4113.58 g/mol (chemical formula: C187H291N45O59). High-resolution ESI-MS analysis is used to confirm this exact mass during quality control.
What is the ozempic amino acid sequence and molecular structure?
The ozempic amino acid sequence refers to the identical 31-amino-acid modified GLP-1 structure of semaglutide. In laboratory research, this molecule is analyzed as a synthetic peptide agonist targeting the GLP-1 receptor to evaluate signaling kinetics.
Why is the semaglutide synthetic peptide modified with an Aib residue at position 8?
The alpha-aminoisobutyric acid (Aib) substitution at position 8 introduces steric protection around the N-terminal cleavage site targeted by dipeptidyl peptidase-4 (DPP-4). This modification prevents rapid enzymatic inactivation in experimental biological media.
How should semaglutide research peptides be reconstituted for in vitro assays?
Lyophilized semaglutide research peptides should be reconstituted in sterile aqueous buffers or bacteriostatic water at neutral pH (7.2–7.4). Avoid high-shear vortexing to prevent self-assembly or aggregation driven by the fatty diacid chain.
What analytical tests verify the identity of semaglutide peptides?
Purity and structural identity of semaglutide peptides are verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for chemical purity (>99%) and Mass Spectrometry (ESI-MS/MALDI-TOF) for sequence confirmation and molecular weight verification.
How does semaglutide compare to dual receptor agonists like tirzepatide in research models?
While semaglutide is a selective single-agonist targeting the GLP-1 receptor, compounds like tirzepatide are engineered to co-activate both GLP-1 and GIP receptors. Comparative in vitro studies allow researchers to observe differences in cAMP generation and downstream beta-arrestin recruitment.
What endotoxin specifications are required for semaglutide research compounds?
High-quality semaglutide synthetic peptide lots manufactured by PX1 Research undergo LAL chromogenic endotoxin testing to guarantee endotoxin levels remain below 0.01 EU/mg, preventing confounding inflammatory responses in cell culture models.
Where can researchers find third-party COAs for peptides semaglutide standards?
PX1 Research provides comprehensive, lot-specific Certificates of Analysis (COAs) for all semaglutide reference standards. Each COA includes complete HPLC chromatograms, mass spectrometry reports, and endotoxin assay data downloadable via our laboratory platform.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.